^
Association details:
Biomarker:TYRP1 overexpression
Cancer:Melanoma
Drug Class:T-lymphocyte cell therapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

LB152 - CAR-T cell therapy for melanoma targeting surface expression of TYRP-1

Published date:
04/09/2021
Excerpt:
Upon co-culture with a panel of human melanoma cell lines with high expression of TYRP-1, the newly developed CAR-T cell therapy leads to tumor cell growth inhibition (94.4% ±0.9 in M207 melanoma cells...Additionally, it induces tumor growth control or tumor elimination after adoptive transfer of CAR-T cells in immunocompromised mice bearing human tumors established from the same cell lines (100% Complete responses (CR) in M207 and 90% CR in M249 tumor models at the end of the experiment).